This study focuses on patients with castration-resistant prostate cancer that has spread to the bones (bone metastases). The research compares two treatment approaches: using enzalutamide alone versus combining enzalutamide with radium-223 dichloride. Enzalutamide is a medication that blocks the effects of male hormones in the body, while radium-223 dichloride is a radioactive substance that targets cancer cells in the bones.
The purpose of this study is to determine if using both medications together works better than using enzalutamide by itself in patients who have either no symptoms or mild symptoms from their cancer. The study will evaluate how well these treatments prevent the cancer from getting worse based on imaging scans.
During the study, patients will receive either enzalutamide capsules taken by mouth daily, or enzalutamide capsules plus radium-223 dichloride given through an intravenous injection. The treatment period may last up to 120 weeks for enzalutamide and 24 weeks for radium-223 dichloride. Patients will also receive medications to protect their bones during the treatment.
Belgium 
Denmark 
France 
Ireland 
Italy 
Norway 
Poland 
Spain 
